Suppr超能文献

1000例小肝细胞癌患者肝切除手术的经验。

Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma.

作者信息

Zhou X D, Tang Z Y, Yang B H, Lin Z Y, Ma Z C, Ye S L, Wu Z Q, Fan J, Qin L X, Zheng B H

机构信息

Liver Cancer Institute, Zhong Shan Hospital, Shanghai Medical University, Shanghai, People's Republic of China.

出版信息

Cancer. 2001 Apr 15;91(8):1479-86. doi: 10.1002/1097-0142(20010415)91:8<1479::aid-cncr1155>3.0.co;2-0.

Abstract

BACKGROUND

Recently, the implementation of screening programs using alpha-fetoprotein (AFP) and ultrasonography in high risk populations has identified increasing numbers of patients with small hepatocellular carcinoma (small HCC). The aim of this study was to summarize the authors' experience in patients who underwent hepatectomy for small HCC and the factors that influence or improve long term survival.

METHODS

The study included 1000 patients who underwent hepatectomy for small HCC (< or = 5 cm) and compared them with 1366 patients who underwent hepatectomy for large HCC (> 5 cm) during the same period. A Cox proportional-hazards model was used for multivariate analysis of prognostic factors.

RESULTS

Comparison between patients with small HCC (n = 1000 patients) and patients with large HCC (n = 1366 patients) revealed that those with small HCC had a higher resection rate (93.6% [1000 of 1068 patients] vs. 55.7% [1366 of 2451 patients]; P < 0.01), a higher curative resection rate (80.5% [805 of 1000 patients] vs. 60.7% [829 of 1366 patients]; P < 0.01), a lower operative mortality rate (1.5% [15 of 1000 patients] vs. 3.7% [50 of 1366 patients]; P < 0.01), better differentiation of tumor cells (Edmondson Grade 3-4; 14.9% vs. 20.1%; P < 0.01), a higher incidence of single nodule tumors (82.6% vs. 64.4%; P < 0.01), a higher proportion of well encapsulated tumors (73.3% vs. 46.3%; P < 0.01), a lower incidence of tumor emboli in the portal vein (4.9% vs. 20.8%; P < 0.01), and higher survival rates after undergoing resection (5 years: 62.7% vs. 37.1%; P < 0.01; 10 years: 46.3% vs. 29.2%; P < 0.01). No significant difference was found between survival after undergoing minor resection (n = 949 patients) or lobectomy (n = 51 patients) in patients with small HCC (P > 0.05). Reresection for subclinical recurrence or solitary pulmonary metastasis after small HCC resection was undertaken in 84 patients.

CONCLUSIONS

Resection is still the modality of first choice for the treatment of patients with small HCC. Minor resection instead of lobectomy was the key to increasing resectability and decreasing operative mortality, and reresection for subclinical recurrence or solitary pulmonary metastasis was important approach to prolonging survival further.

摘要

背景

最近,在高危人群中采用甲胎蛋白(AFP)和超声检查实施筛查计划,已发现越来越多的小肝细胞癌(小肝癌)患者。本研究的目的是总结作者对小肝癌患者行肝切除术的经验以及影响或改善长期生存的因素。

方法

本研究纳入了1000例行小肝癌(≤5cm)肝切除术的患者,并将其与同期1366例行大肝癌(>5cm)肝切除术的患者进行比较。采用Cox比例风险模型对预后因素进行多因素分析。

结果

小肝癌患者(n = 1000例)与大肝癌患者(n = 1366例)的比较显示,小肝癌患者的切除率更高(93.6%[1068例中的1000例]对55.7%[2451例中的1366例];P<0.01),根治性切除率更高(80.5%[1000例中的805例]对60.7%[1366例中的829例];P<0.01),手术死亡率更低(1.5%[1000例中的15例]对3.7%[1366例中的50例];P<0.01),肿瘤细胞分化更好(Edmondson 3-4级;14.9%对20.1%;P<0.01),单结节肿瘤发生率更高(82.6%对64.4%;P<0.01),包膜完整的肿瘤比例更高(73.3%对46.3%;P<0.01),门静脉肿瘤栓子发生率更低(4.9%对20.8%;P<0.01),切除术后生存率更高(5年:62.7%对37.1%;P<0.01;10年:46.3%对29.2%;P<0.01)。小肝癌患者行局部切除(n = 949例)或肝叶切除(n = 51例)后的生存率无显著差异(P>0.05)。84例小肝癌切除术后因亚临床复发或孤立性肺转移而行再次切除。

结论

肝切除术仍是小肝癌患者治疗的首选方式。局部切除而非肝叶切除是提高切除率和降低手术死亡率的关键,因亚临床复发或孤立性肺转移而行再次切除是进一步延长生存期的重要方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验